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Bridging the gap to evidence-based 
eye care
In the ﬁrst article in this series, I touched on 
the enormous challenge to make access 
to information equal for those who need it 
at the time and place when they need it. 
Only if this is achieved can we successfully 
promote an evidence-based approach to 
health care. The move towards open access 
publishing is taking us some way to achieving 
this. However, there are further gaps to be 
bridged if we are to turn eye care workers 
into evidence-based practitioners. We can 
deﬁne an evidence-based practitioner as one 
who combines their individual knowledge 
and expertise with the best available external 
clinical evidence from systematic research. 
The standard approach to evidence-
based health care is: 
1 Formulating a question
2 Looking for evidence, which usually 
means searching the scientiﬁc literature
3 Appraising the information, 
i.e. deciding if it is reliable 
4 Applying the evidence
5 Evaluating the process.
Formulating a question
The ﬁrst gap we need to bridge relates to 
the way that health care providers think 
about knowledge and information. Asking 
a question might be difﬁcult for those who 
have been taught to practice medicine 
by rote, memorising lists of causes and 
treatments without ever being taught to 
ask the question “why?” or “how do you 
know?” Creating a thirst for knowledge, 
and encouraging people to practice it, is 
the challenge for implementing evidence-
based practice in ophthalmology. 
An important starting point is to challenge 
anything new; just because it is new, it does 
not necessarily follow that it is better. It is 
almost certainly going to be more expensive 
so what additional beneﬁt is there to justify 
the additional cost? But it is almost as 
important to challenge established practice. 
Just because we always do things in certain 
ways does not mean it’s the best way of 
doing it. How many of our readers continue 
to treat corneal abrasion with antibiotic 
ointment and a pad? The few trials that have 
been conducted suggest that padding slows 
healing and increases discomfort. There is 
no evidence that padding reduces the risk 
of secondary infection (though this might be 
more of a concern in poorer countries with 
less sanitation or dusty environments from 
where no such studies have been reported).
Looking for evidence
Once we have a question, the search for an 
answer follows, and here lies another gap. 
As already stated, there are major inequal-
ities in access to and availability of reliable 
information sources. A major problem is 
that the holders of information demand 
payment for access. The amount to pay is 
rarely adjusted for ability to pay and prices 
are set by richer economies. Looking for 
evidence can also be a time consuming 
process, time which a busy clinician in 
an overwhelmed and under resourced 
outpatient clinic will rarely, if ever, have. 
Those with internet access can run simple 
searches to ﬁnd answers. However, of the 
evidence available, the average searcher 
will ﬁnd only a fraction, which is why services 
which synthesise and evaluate research, 
such as The Cochrane Library, are valuable. 
Appraising the information
Once we have found sources of information 
to answer our question, we must appraise 
it – is this information reliable? The 
challenge to evidence-based health care 
is to ensure that information is reliable, of 
good quality, free from bias and not linked 
to the personal advantage of any individual 
or group of individuals. It should be available 
and accessible to users of information in 
a form that is interpretable and relevant. It 
should also be quality controlled. How then 
is evidence graded? What hierarchies are 
used for judging the quality of evidence? 
Table 1 gives an example of one such 
hierarchy from the Canadian Task Force 
on Preventive Health Care. Randomised 
controlled trials (RCTs) provide the best 
evidence for the effectiveness of interven-
tions because the control group provides the 
comparator (which allows us to quantify an 
estimate of the effectiveness of a treatment) 
and randomisation prevents bias in selecting 
who gets treated and who is a control. It also 
deals with the possibility of baseline dissim-
ilarities between treatment and control 
groups which may account for the outcome 
of the trial rather than the intervention; 
these are termed confounders which may 
be apparent or hidden. The randomised 
controlled trial, and especially the systematic 
review of several random controlled trials, is 
more likely to inform us than mislead us.
I Evidence from randomized controlled trial(s)
II-1 Evidence from controlled trial(s) without randomization
II-2 Evidence from cohort or case-control analytic studies, preferably from more than one centre or research group
II-3 Evidence from comparisons between times or places with or without the intervention; dramatic results in uncontrolled experiments 
 could be included here
III Opinions of respected authorities, based on clinical experience; descriptive studies or reports of expert committees
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Table 1. Levels of Evidence – Research Design Rating
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Human beings are usually rather quick 
to attribute cause and effect. Traditional 
methods of healing rely on QED (Quod est 
demonstrandum – as is demonstrated) type 
evidence. The patient was ill, the doctor 
treated and the patient recovered. Thus the 
treatment was effective. We forget that the 
patient may have got better anyway and 
that the treatment may have been sham 
or placebo. Hence it is only RCTs which 
can properly attribute cause and effect 
and additionally estimate how powerful the 
effect of an intervention is; not just does 
it work, yes or no, but by how much is the 
probability of an adverse outcome reduced 
or a beneﬁt increased. One intuitively 
useful measure of effect which can be 
derived from trials is the NNT – the number 
needed to treat for one to beneﬁt. For ocular 
hypertension, this may be as high as 40.
Other types of study, cohort and case 
control, often called observational studies, 
can quantify effect or risk but are more prone 
to bias and confounding. But the commonest 
type of medical report in ophthalmology, the 
case series (where there is no comparator 
or control group) is not only likely to be 
biased through selection but also cannot 
provide an estimate of effect size. It is that 
very basic sort of evidence, the QED type, 
which surgeons and eye doctors often 
seem to think sufﬁcient. Much needs to 
be done to educate clinicians about the 
nature and quality of evidence on which 
we base our practice. It is also necessary 
to apply quality control to the studies 
themselves. RCTs vary greatly in quality, and 
stringent criteria for evaluating the quality 
of individual studies need to be applied. 
Applying the evidence
One common difﬁculty in relating existing 
evidence to the patient in front of you is that 
your patient may have little in common with 
the subjects who participated in the trials. 
This is the external validity of a trial. If the 
inclusion/exclusion criteria are so tight that 
only a small sample of the population at 
risk of the effects of a disease are included, 
it can be difﬁcult to interpret and apply the 
evidence. For example, in chronic glaucoma, 
we only have evidence of the effectiveness 
of lowering intraocular pressure in ocular 
hypertensives, people with early manifest 
glaucoma and normal tension glaucoma 
because these are the only patient groups 
included in trials where treatment has been 
compared to none. And apart from a few 
African Americans, the patients were all 
white Europeans. How far can we apply 
those ﬁndings to the populations of the rest 
of the world? Another gap occurs for people 
who are routinely excluded from trials, 
such as pregnant women and children.
Implementing evidence in practice is 
difﬁcult to achieve and doctors often only 
use evidence if it ﬁts with their pre-existing 
beliefs. One strategy is for agencies to 
develop evidence-based guidelines. There 
are numerous examples of guidelines 
which are not evidence-based since these 
are much easier to produce. Usually, 
these are developed using a select group 
of ‘experts’ whose dominant opinion 
becomes the basis of recommended 
practice. This is not evidence-based.
Evaluating the process
The ﬁnal step in evidence-based practice is to 
monitor the effectiveness of interventions in 
the real world. Trials are clinical experiments 
conducted in carefully controlled conditions. 
It is well known that outcomes in trials tend 
to be better than in ordinary clinics and this is 
another gap between evidence and practice. 
Regular monitoring of outcomes is therefore 
an important part of the evidence base.
Personal audit is an excellent means 
for surgeons to monitor and improve their 
practice. Research is ongoing to develop 
a simple database for use in VISION 
2020 programmes globally. Large-scale 
representative studies of outcomes are 
important to establish standards which can 
be used for audit. Several large outcome 
studies for cataract surgery have been 
conducted such as those in the USA, UK and 
Scandinavia. The latter is a large register 
of cataract surgery in Sweden which allows 
monitoring of rare but important adverse 
events such as endophthalmitis and also 
provides information on effectiveness of 
prophylactic measures which cannot be 
detected in trials (since they are never 
large enough to detect differences in the 
occurrence of rare events). Registers 
have been important in establishing the 
evidence base for corneal transplantation.
Adverse events can also be monitored 
by surveillance systems and are in place 
in many Western countries for collecting 
information on the adverse effects of 
drugs. However, few are yet established for 
surgery, and such information collection is 
impossible in poorer countries. Global efforts, 
perhaps VISION 2020, will in time provide 
the infrastructure for such surveillance.
Conclusion
Compared to other specialties, ophthal-
mology has a long way to go in developing 
its evidence base. I have peer refereed a 
systematic review for the Cochrane Tobacco 
and Addiction group which included more 
than 90 randomised controlled trials for 
nicotine replacement therapy. In our review 
on Ivermectin for onchocerciasis, we could 
ﬁnd only ﬁve relevant studies. This reﬂects 
the enormous bias (reﬂecting the availa-
bility of research resources) towards evidence 
for diseases affecting afﬂuent nations. 
But there is also a need for ophthal-
mologists (like many other surgically 
dominated specialties) to recognise 
the importance of evidence beyond 
QED in informing their practice.
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‘Creating a thirst for knowledge, and providing 
the tools to access, assess and apply it, is the 
challenge for implementing evidence-based practice 
in ophthalmology.’
Treatment for Retinopathy of Prematurity 
(ROP) is one area of eye care for which the 
evidence base is well developed. There are 
four systematic reviews on The Cochrane 
Library on the subject. The library can be 
accessed via Hinari for lower income 
countries at www.healthInternetwork.org
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